NasdaqGM - Delayed Quote USD

Horizon Kinetics Medical ETF (MEDX)

27.44 -0.05 (-0.18%)
At close: April 18 at 4:00 PM EDT
Loading Chart for MEDX
DELL
  • Previous Close 27.49
  • Open 27.40
  • Bid 25.59 x 100
  • Ask 29.46 x 100
  • Day's Range 27.40 - 27.44
  • 52 Week Range 27.02 - 32.16
  • Volume 128
  • Avg. Volume 796
  • Net Assets 17.74M
  • NAV 27.50
  • PE Ratio (TTM) 17.19
  • Yield 1.30%
  • YTD Daily Total Return -1.77%
  • Beta (5Y Monthly) 0.56
  • Expense Ratio (net) 0.85%

The fund is an actively-managed exchange-traded fund (“ETF”) that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.

Horizon Kinetics

Fund Family

Health

Fund Category

17.74M

Net Assets

1999-09-30

Inception Date

Performance Overview: MEDX

Trailing returns as of 4/18/2024. Category is Health.

YTD Return

MEDX
1.77%
Category
6.33%
 

1-Year Return

MEDX
5.76%
Category
11.04%
 

3-Year Return

MEDX
1.69%
Category
0.38%
 

People Also Watch

Holdings: MEDX

Top 10 Holdings (61.67% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 14.73%
ABBV
AbbVie Inc. 7.88%
BMY
Bristol-Myers Squibb Company 5.43%
AMGN
Amgen Inc. 5.38%
NVS
Novartis AG 5.23%
JNJ
Johnson & Johnson 5.14%
MRK
Merck & Co., Inc. 5.00%
AZN
AstraZeneca PLC 4.77%
CRSP
CRISPR Therapeutics AG 4.06%
PFE
Pfizer Inc. 4.05%

Sector Weightings

SectorMEDX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Related ETF News

Research Reports: MEDX

  • NBIX: Lowering target price to $140.00

    NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $140.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     
  • LGND: Lowering target price to $84.00

    LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $84.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • LGND: Raising target price to $86.00

    LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • MYGN: Lowering target price to $19.00

    MYRIAD GENETICS INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Bearish
    Price Target
     

Related Tickers